Botulinum toxin use in paediatric colorectal surgery

Pediatr Surg Int. 2014 Aug;30(8):833-8. doi: 10.1007/s00383-014-3536-4. Epub 2014 Jul 6.

Abstract

Purpose: To evaluate outcomes of intrasphincteric botulinum toxin injection (ISBTI) in children with intractable constipation.

Methods: Retrospective case-note review of patients ≤ 16 years of age undergoing ISBTI between January 2010 and February 2014. Data collected included patient demographics, diagnosis, complications, follow-up duration and functional outcomes. Successful outcome was defined as resolution/improvement in symptoms and failed when there was no change in symptoms. Statistical analyses were performed using PRISM (GraphPad, CA, USA). p values <0.05 were considered as significant.

Results: 43 patients [male 29, median age 5 years 9 months (range 13 months-13 years 5 months)] underwent 86 ISBTIs. Underlying diagnoses were idiopathic constipation (67 %), Hirschsprung disease (26 %), anorectal malformation (5 %), gastrointestinal dysmotility (2 %). 72 % (31/43) reported improvement in symptoms after the first ISBTI. 39 % of patients had recurrence of symptoms at 12-month median follow-up. 10 patients non-responsive to ISBTI required an antegrade continence enema or stoma. There was no correlation between age (p = 0.3), gender (p = 0.7), diagnosis (p = 0.84), or number of ISBTIs (p = 0.17) with successful outcome.

Conclusion: Successful outcomes occurred in 72 % patients after the first ISBTI. 25 % required further surgical management of their symptoms. Further work is required to help predict which patients will benefit from ISBTI.

MeSH terms

  • Adolescent
  • Anal Canal / surgery*
  • Botulinum Toxins, Type A / therapeutic use*
  • Child
  • Child, Preschool
  • Colorectal Surgery*
  • Constipation / therapy*
  • Fecal Incontinence / therapy*
  • Female
  • Hirschsprung Disease / therapy*
  • Humans
  • Infant
  • Male
  • Neuromuscular Agents / therapeutic use
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A